Ascendis Pharma (ASND) A/S announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral presentation today by Andrea Palermo, M.D., from the Campus Bio-Medico University, during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology and the European Society of Endocrinology.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma announces it will share latest data at ESPE & ESE 2025
- Ascendis Pharma’s Strong Yorvipath Launch and Promising Pipeline Boost Buy Rating and Price Target
- Promising Outlook for Ascendis Pharma: Strong Yorvipath Sales and Positive Market Feedback Justify Buy Rating
- Ascendis Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
- Ascendis Pharma’s Earnings Call: Growth Amid Challenges